Search

Displaying results 4011 - 4020 of 10000 in total
  1. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  2. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.

    Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
  3. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  4. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  5. Drug

    Platelet Lysate

    go.drugbank.com/drugs/DB15869
    Investigational

    Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.

  6. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). … a greater affinity for free serum IgE and an altered sensitivity to IgE conformation.

  7. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

  8. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    in Parkinson’s disease. … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the

  9. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

  10. Drug

    Rotavirus vaccine

    go.drugbank.com/drugs/DB10276
    ApprovedInvestigational

    [Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.[L1117]